Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
October 5, 2022
January 11, 2023
791723ae-658a-431c-8b44-6ba50a528579
Related Documents
Assessing User Fees Under the Biosimilar User Fee Amendments of 2022: Guidance for Industry
Guidance DocumentJuly 31, 2023Center for Drug Evaluation and Research
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022
Guidance DocumentMay 1, 2023Center for Drug Evaluation and Research
ANDA Submissions – Prior Approval Supplements Under GDUFA: Guidance for Industry
Guidance DocumentOctober 14, 2022Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox